BXMT Q2 2025 Earnings Call Highlights
BXMT reported Q2 2025 net revenue of $12.5 million, up 45% year-over-year and 44% sequentially, driven by commercial execution in PKD and increased units processed. The company also announced progress in PYRUKYND patient enrollment and FDA decision timelines for its thalassemia indication.
Topics: commercialization earnings FDA approval PYRUKYND R&D revenue